Report
Soomit Datta
EUR 9318.00 For Business Accounts Only

ENTEL (Neutral, TP: CLP3,150, -0.3%) Entel - Better Chilean Wireless optics (though market still tough); reinvesting in Fixed

Entel reported Q4s yesterday after the close. Revenue and EBITDA came in 6-7% (when removing revenue linked to the fibre sale) though this was partly driven by handset sales. Wireless service trends also beat in Chile, and were optically impressive, though in reality enjoyed a much easier comp (Q4 22); we’re not convinced the fundamentals are getting any better and we note price increases for 2024 have yet to be committed to.
Underlying
Empresa Nacional de Telecomunicaciones S.A.

Empresa Nacional de Telecomunicaciones is engaged in the provision of telecommunication services. Services provided include local, domestic and international long-distance calls, international direct dialing, international directory assistance, international business toll-free service, mobile maritime service via satellite, video conference, international telephone cards, bank credit cards, collect calls, television and radio transmission services, and private corporate networks through a digital network offering voice, data, fax, image and internet services.

Provider
New Street Research
New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Analysts
Soomit Datta

Other Reports on these Companies
Other Reports from New Street Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch